Pilot Trial of Rituximab (Rituxan) for the Prevention of EBV-LPD Post T Cell Depleted Unrelated and HLA Mis-matched Related HSCT
Phase of Trial: Phase II
Latest Information Update: 12 Feb 2016
At a glance
- Drugs Rituximab (Primary)
- Indications Graft-versus-host disease; Lymphoproliferative disorders
- Focus Adverse reactions
- 17 Dec 2008 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
- 17 Dec 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Apr 2008 New trial record.